Sofosbuvir/velpatasvir/voxilaprevir

Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination medication used in the treatment of hepatitis C. It contains three active ingredients: sofosbuvir, velpatasvir, and voxilaprevir. This combination therapy is marketed under the brand name Vosevi by Gilead Sciences.

Composition[edit | edit source]

The medication is composed of three direct-acting antiviral drugs: sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir is a nucleotide analogue hepatitis C virus (HCV) NS5B polymerase inhibitor, velpatasvir is an HCV NS5A inhibitor, and voxilaprevir is an HCV NS3/4A protease inhibitor.

Usage[edit | edit source]

Sofosbuvir/velpatasvir/voxilaprevir is used to treat adults with chronic hepatitis C genotype 1-6, either without cirrhosis or with compensated cirrhosis, who have previously been treated with an NS5A inhibitor-containing regimen.

Efficacy[edit | edit source]

Clinical trials have shown that the combination of sofosbuvir, velpatasvir, and voxilaprevir is highly effective in curing hepatitis C. The cure rates are typically over 90%, even in patients with cirrhosis or those who have previously failed other treatments.

Side Effects[edit | edit source]

Common side effects of sofosbuvir/velpatasvir/voxilaprevir include headache, fatigue, diarrhea, and nausea. Serious side effects may include reactivation of hepatitis B in those who have previously been infected.

Approval[edit | edit source]

The combination of sofosbuvir, velpatasvir, and voxilaprevir was approved for medical use in the United States in 2017. It is on the World Health Organization's List of Essential Medicines.